Anthem Biosciences Limited

Anthem Biosciences Ltd share price inched up 1.66% to Rs 854.5 after the company's net profit jumped 76.30% to Rs 211.46 crore, while revenue from operations gained significantly 42.04% to Rs 594.03 crore in Q3FY26 over Q2FY26. The market capitalization of Biotechnology industry group stocks on BSE stood at Rs 50687.47 crore, expanding by 26.37%. It has improved by 2.88% over last one week and crept higher by 1.46% in last one month while the market capitalization of Anthem Biosciences Ltd has marginally improved by 2.72% and 3.54% in the same period respectively. Profit before tax (PBT) of Anthem Biosciences Ltd stood at Rs 296.37 crore in Q3 FY26, rallying 29.08% year-on-year, and surging by 104.99% quarter-on-quarter. EBITDA came in at Rs 213 crore, jumping 25.30% YoY and surging by 69.16% sequentially. Total expenses went up by 18.68% to Rs 353.25 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 200.77 crore, witnessing a sharp rise of 35.14% YoY, while employee benefits expense was at Rs 81.25 crore, inching up 3.06% YoY. For the TTM ended FY26, revenue from operations grew 15.17% to Rs 2124.33 crore, while net profit saw a strong growth of 31.14% to Rs 591.79 crore, compared to previous TTM. EBITDA jumped by 62881% to Rs 678.03 crore, and PBT soared 25.48% to Rs 824.24 crore compared to previous TTM. The company's consolidated net cash flow from operating activities stood at Rs 844.49 crore in FY26, as against Rs 270.55 crore in FY25. Anthem Biosciences Ltd rallied 21.61% in last one year, significantly outperforming the benchmark BSE Sensex which has eased by 8.41% during the same period.

Anthem Biosciences Limited will hold a board meeting on November 3, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, according to a regulatory filing with the BSE Limited and National Stock Exchange of India Limited. The trading window for the company's equity shares has been closed from October 1, 2026, until November 5, 2026, in compliance with SEBI regulations.

Anthem Biosciences Limited, formerly known as Anthem Biosciences Private Limited, submitted a certificate to the BSE Limited and National Stock Exchange of India Limited on October 9, 2026, detailing securities dematerialized and rematerialized for the quarter ended September 30, 2026, as per Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018; the certificate was received from Kfin Technologies Limited, the company’s Registrar and Transfer Agent, on October 2, 2026.

Anthem Biosciences Limited, formerly known as Anthem Biosciences Private Limited, will close its trading window for designated persons from October 1, 2026, until 48 hours after a board meeting to approve financial results for the quarter and half year ending September 30, 2026, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Net profit of Anthem Biosciences declined 11.67% to Rs 119.94 crore in the quarter ended June 2026 as against Rs 135.79 crore during the previous quarter ended June 2025. Sales declined 22.58% to Rs 418.22 crore in the quarter ended June 2026 as against Rs 540.21 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales418.22540.21 -23 OPM %36.0035.45 - PBDT174.57212.69 -18 PBT144.58186.25 -22 NP119.94135.79 -12 Powered by Capital Market - Live

Anthem Biosciences will hold a meeting of the Board of Directors of the Company on 21 July 2026.

Anthem Biosciences announced that the 20th Annual General Meeting(AGM) of the company will be held on 22 July 2026.

Anthem Biosciences announced that the Board of Directors of the Company at its meeting held on 19 May 2026, inter alia, have recommended the final dividend of Rs 2 per equity Share (i.e. 100%) , subject to the approval of the shareholders.

Net profit of Anthem Biosciences rose 129.68% to Rs 189.76 crore in the quarter ended March 2026 as against Rs 82.62 crore during the previous quarter ended March 2025. Sales rose 26.44% to Rs 610.94 crore in the quarter ended March 2026 as against Rs 483.20 crore during the previous quarter ended March 2025. For the full year,net profit rose 31.14% to Rs 591.79 crore in the year ended March 2026 as against Rs 451.26 crore during the previous year ended March 2025. Sales rose 15.17% to Rs 2124.33 crore in the year ended March 2026 as against Rs 1844.55 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales610.94483.20 26 2124.331844.55 15 OPM %43.7440.40 -39.2536.37 - PBDT316.53208.73 52 982.70746.24 32 PBT276.94178.31 55 848.63656.87 29 NP189.7682.62 130 591.79451.26 31 Powered by Capital Market - Live

Anthem Biosciences will hold a meeting of the Board of Directors of the Company on 19 May 2026.